10. BioDelivery Sciences International (BDSI - Get Report) is development-stage, specialty pharmaceutical company using licensed and proprietary drug delivery technologies to develop and commercialize new therapeutic formulations.
BioDelivery recently refuted a patent infringement lawsuit filed by MonoSol RX. In a press release, Dr. Mark A. Sirgo, president and CEO, said, "Our manufacturing process for ONSOLIS, which MonoSol asserts infringes its process patent, is a trade secret for which no one has any access. MonoSol has failed to disclose any basis for its assertion that our confidential, proprietary manufacturing process infringes its newly-issued patent." He added, "Importantly, we have not and will not allow this meritless claim to distract us from driving our promising development pipeline forward including our aggressive pursuit of BEMA Buprenorphine for the treatment of chronic pain and BEMA Buprenorphine/Naloxone for the treatment of opioid dependence."
The stock will likely provide an upside of 91% over the next 12 months with a consensus target price of $6.3, according to analysts polled by Bloomberg. In comparison, Hospira (HSP), Watson Pharmaceuticals (WPI), Cephalon (CEPH), King Pharmaceuticals (KG) and Akorn (AKRX) are likely to return around 27%, 8%, 24%, -5% and 45%, respectively.
All the four analysts covering the stock recommend buying.